This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ethyl-EPA Treatment of Prodromal Patients

This study has been completed.
Information provided by (Responsible Party):
Yale University Identifier:
First received: March 6, 2008
Last updated: May 21, 2014
Last verified: May 2014
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Condition Intervention Phase
Schizophrenia Prodrome Drug: ethyl-eicosapentaenoic acid Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ethyl-EPA Treatment of Prodromal Patients

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • conversion to psychosis [ Time Frame: one year ]

Enrollment: 7
Study Start Date: September 2001
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: ethyl-eicosapentaenoic acid
2 mg per day
Other Name: ethyl-EPA, an omega-3 fatty acid


Ages Eligible for Study:   14 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • meets criteria for schizophrenia prodrome

Exclusion Criteria:

  • any lifetime antipsychotic treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00634361

Sponsors and Collaborators
Yale University
Principal Investigator: Scott W Woods, MD Yale University
  More Information

Responsible Party: Yale University Identifier: NCT00634361     History of Changes
Obsolete Identifiers: NCT00237835
Other Study ID Numbers: LA01.03.0011
Study First Received: March 6, 2008
Last Updated: May 21, 2014

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on September 21, 2017